GR3006141T3 - - Google Patents

Info

Publication number
GR3006141T3
GR3006141T3 GR920402185T GR920402185T GR3006141T3 GR 3006141 T3 GR3006141 T3 GR 3006141T3 GR 920402185 T GR920402185 T GR 920402185T GR 920402185 T GR920402185 T GR 920402185T GR 3006141 T3 GR3006141 T3 GR 3006141T3
Authority
GR
Greece
Application number
GR920402185T
Other languages
Greek (el)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3006141T3 publication Critical patent/GR3006141T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR920402185T 1987-04-16 1992-11-04 GR3006141T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873712985 DE3712985A1 (de) 1987-04-16 1987-04-16 Bifunktionelle proteine

Publications (1)

Publication Number Publication Date
GR3006141T3 true GR3006141T3 (cg-RX-API-DMAC7.html) 1993-06-21

Family

ID=6325799

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402185T GR3006141T3 (cg-RX-API-DMAC7.html) 1987-04-16 1992-11-04

Country Status (20)

Country Link
EP (1) EP0288809B1 (cg-RX-API-DMAC7.html)
JP (1) JP2667193B2 (cg-RX-API-DMAC7.html)
KR (1) KR970000187B1 (cg-RX-API-DMAC7.html)
AR (1) AR242991A1 (cg-RX-API-DMAC7.html)
AT (1) ATE79135T1 (cg-RX-API-DMAC7.html)
AU (1) AU613022B2 (cg-RX-API-DMAC7.html)
CA (1) CA1322157C (cg-RX-API-DMAC7.html)
DE (2) DE3712985A1 (cg-RX-API-DMAC7.html)
DK (1) DK170741B1 (cg-RX-API-DMAC7.html)
ES (1) ES2033981T3 (cg-RX-API-DMAC7.html)
FI (1) FI98830C (cg-RX-API-DMAC7.html)
GR (1) GR3006141T3 (cg-RX-API-DMAC7.html)
HU (1) HU204303B (cg-RX-API-DMAC7.html)
IE (1) IE61574B1 (cg-RX-API-DMAC7.html)
IL (1) IL86086A (cg-RX-API-DMAC7.html)
NO (1) NO176922C (cg-RX-API-DMAC7.html)
NZ (1) NZ224247A (cg-RX-API-DMAC7.html)
PH (1) PH25327A (cg-RX-API-DMAC7.html)
PT (1) PT87237B (cg-RX-API-DMAC7.html)
ZA (1) ZA882659B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US5108910A (en) * 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
WO2001040311A1 (fr) * 1999-11-30 2001-06-07 Shionogi & Co., Ltd. Proteine fusionnee de chimiokine slc-il2
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ES2356154T3 (es) * 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
WO2010001414A1 (en) * 2008-07-03 2010-01-07 Lupin Limited Expression of heterologous proteins in bacterial system using a gm-csf fusion tag

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8327880D0 (en) * 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
WO1985004673A1 (fr) * 1984-04-10 1985-10-24 Takeda Chemical Industries, Ltd. Nouvel adn et son utilisation
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JPS61128889A (ja) * 1984-11-27 1986-06-16 Green Cross Corp:The 組換えｄｎａ及び該ｄｎａによる形質転換体
JPH0646957B2 (ja) * 1985-03-11 1994-06-22 武田薬品工業株式会社 インタ−ロイキン−２の製造方法
WO1987002060A1 (en) * 1985-10-03 1987-04-09 Biogen N.V. Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
KR970000187B1 (ko) 1997-01-06
PH25327A (en) 1991-04-30
DE3873397D1 (de) 1992-09-10
EP0288809A1 (de) 1988-11-02
JP2667193B2 (ja) 1997-10-27
NO176922B (no) 1995-03-13
IE881146L (en) 1988-10-16
AU1466188A (en) 1988-10-20
ATE79135T1 (de) 1992-08-15
IE61574B1 (en) 1994-11-16
PT87237A (pt) 1988-05-01
FI98830C (fi) 1997-08-25
JPS63301898A (ja) 1988-12-08
IL86086A (en) 1995-01-24
DE3712985A1 (de) 1988-11-03
AR242991A1 (es) 1993-06-30
NO881658L (no) 1988-10-17
NO881658D0 (no) 1988-04-15
AU613022B2 (en) 1991-07-25
CA1322157C (en) 1993-09-14
PT87237B (pt) 1992-07-31
EP0288809B1 (de) 1992-08-05
NZ224247A (en) 1990-04-26
FI881743A0 (fi) 1988-04-14
NO176922C (no) 1995-06-21
KR880012760A (ko) 1988-11-29
ZA882659B (en) 1988-10-14
DK209188D0 (da) 1988-04-15
DK170741B1 (da) 1996-01-08
FI881743L (fi) 1988-10-17
HU204303B (en) 1991-12-30
DK209188A (da) 1988-10-17
ES2033981T3 (es) 1993-04-01
IL86086A0 (en) 1988-09-30
FI98830B (fi) 1997-05-15
HUT47319A (en) 1989-02-28

Similar Documents

Publication Publication Date Title
DE3881300D1 (cg-RX-API-DMAC7.html)
DE3882183D1 (cg-RX-API-DMAC7.html)
IN168768B (cg-RX-API-DMAC7.html)
IN171465B (cg-RX-API-DMAC7.html)
IN168955B (cg-RX-API-DMAC7.html)
GR3007314T3 (cg-RX-API-DMAC7.html)
ATA244887A (cg-RX-API-DMAC7.html)
IN169032B (cg-RX-API-DMAC7.html)
AU6301290A (cg-RX-API-DMAC7.html)
AU5406686A (cg-RX-API-DMAC7.html)
AU6799487A (cg-RX-API-DMAC7.html)
AU5846886A (cg-RX-API-DMAC7.html)
AU7093087A (cg-RX-API-DMAC7.html)
AU7925291A (cg-RX-API-DMAC7.html)
AU5648086A (cg-RX-API-DMAC7.html)
AU6268886A (cg-RX-API-DMAC7.html)
AU6551986A (cg-RX-API-DMAC7.html)
AU6951987A (cg-RX-API-DMAC7.html)
AU6234086A (cg-RX-API-DMAC7.html)
AU5857686A (cg-RX-API-DMAC7.html)
AU6794887A (cg-RX-API-DMAC7.html)
AU7986487A (cg-RX-API-DMAC7.html)
AU6000786A (cg-RX-API-DMAC7.html)
AU7243387A (cg-RX-API-DMAC7.html)
AU7016787A (cg-RX-API-DMAC7.html)